Ratika Sood, MD
Family Medicine · Glen Burnie, MDNPI 1174819312
Payments from drug & device makers
Across 212 payments — averaging $18.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$696
- Lilly USA, LLC$483
- Novo Nordisk$451
- Pfizer$287
- AstraZeneca$247
- Astellas Pharma US Inc$197
- plus $2K from 27 others
What the payments were for
- Food & beverage$3,934100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 39 | $696 |
| Lilly USA, LLC | 23 | $483 |
| Novo Nordisk | 39 | $451 |
| Pfizer | 13 | $287 |
| AstraZeneca | 12 | $247 |
| Astellas Pharma US Inc | 11 | $197 |
| GSK | 8 | $174 |
| Axsome Therapeutics, Inc. | 7 | $162 |
| Exact Sciences | 6 | $151 |
| Lundbeck LLC | 7 | $136 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $128 |
| Boehringer Ingelheim | 5 | $107 |
| Amgen(2 entities) | 4 | $97 |
| Novartis | 4 | $83 |
| Corcept Therapeutics | 3 | $74 |
| Sanofi-aventis U.S. LLC | 4 | $59 |
| Phathom Pharmaceuticals, Inc. | 3 | $44 |
| Neurocrine Biosciences, Inc. | 2 | $43 |
| Merck | 1 | $29 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Johnson & Johnson | 1 | $28 |
| Alkermes, Inc. | 1 | $25 |
| Bayer | 1 | $23 |
| Sumitomo Pharma America, Inc. | 1 | $23 |
| Seqirus USA Inc | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Dynavax Technologies Corporation | 1 | $18 |
| Life Molecular Imaging Ltd | 1 | $18 |
| Dexcom, Inc. | 1 | $17 |
| Viatris Specialty LLC | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Vertiflex, Inc. | 1 | $11 |
How this compares
$3,934 in reported general payments places this provider in the 85th percentile of 1,193 family medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 20 | $46,219 |
| OzempicSemaglutide | 28 | $45,600 |
| JardianceEmpagliflozin | 21 | $23,040 |
| TrulicityDulaglutide | 16 | $22,536 |
| EliquisApixaban | 15 | $22,084 |
| JanuviaSitagliptin Phosphate | 12 | $17,206 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $5,369 |
| Rosuvastatin Calcium | 93 | $3,260 |
| Atorvastatin Calcium | 181 | $3,199 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $2,415 |
| Olmesartan Medoxomil | 47 | $2,053 |
| Amlodipine Besylate | 175 | $2,004 |
| Losartan Potassium | 137 | $1,911 |
| Metoprolol Succinate | 93 | $1,681 |
| Levothyroxine Sodium | 130 | $1,633 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $483 | $68,75536 claims |
| Novo NordiskOzempic | $451 | $45,60028 claims |
| Boehringer IngelheimJardiance | $107 | $23,04021 claims |
| PfizerEliquis | $287 | $22,08415 claims |
| MerckJanuvia | $29 | $17,20612 claims |
| GSKBreo Ellipta | $174 | $5,36915 claims |
| AstraZenecaSymbicort | $247 | $2,41511 claims |
| AbbVieSynthroid | $696 | $36911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,193 family medicine providers in Maryland.
Other family medicine in Glen Burnie
- Sharon ChungGlen Burnie$333K
- Stephan IzziGlen Burnie$14K
- Vincent IzziGlen Burnie$13K
- Stephen OngOxon Hill$5.9M
- Stephan BartWoodstock$1.7M
- Karen DonaldsonBaltimore$899K
- Rajiv DuaColumbia$765K
- Greg TampusLutherville Timonium$735K
- Louis JacquesBaltimore$522K
- Stephanie MellerOxon Hill$518K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.